Genetic modification of haematopoietic cells for combined resistance to podophyllotoxins, other agents covered by MDR1-mediated efflux activity and nitrosoureas

Bone Marrow Transplantation

Volumn 25, Issue 3332, 2000, Pages

  Baum, C ^a   Peinert, S ^a   Carpinteiro, A ^a   Eckert, H G ^b   Fairbairn, L J ^c  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b BIONTECH AG   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer chemotherapy; Drug resistance; Gene therapy; Haematotoxicity; Oncology; Retroviral vectors

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; CARMUSTINE; COLCHICINE; COMPLEMENTARY DNA; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; NITROSOUREA; PODOPHYLLOTOXIN; VIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DNA MODIFICATION; GENE TRANSFER; HEMATOPOIETIC CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; DRUG RESISTANCE, MULTIPLE; GENES, MDR; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; P-GLYCOPROTEIN; PODOPHYLLOTOXIN; TRANSDUCTION, GENETIC;

EID: 0033932080     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702359     Document Type: Article

References (10)

1. Rafferty JA, Hickson I, Chinnasamy N et al. Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metast Rev 1996; 15: 365-383.
2. Baum C, Fairbairn, L, Hildinger M et al. New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells. Expert reviews in molecular medicine. 1999; http://www-ermm.cbcu.cam.ac.uk
3. 6-alkylating agents in vitro. Gene Therapy 1998; 5: 835-841.
4. 6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Therapy 1999; 6: 1489-1493.
5. Baum C, Forster P, Hegewisch-Becker S, Harbers K. An optimized electroporation protocol applicable to a wide range of cell lines. BioTechniques 1994; 17: 1058-1062.
6. 6-alkylguanine-DNA alkyltransferase. Gene Therapy 1998; 5: 842-847.
7. Hildinger M, Eckert HG, Schilz AJ et al. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced haematopoietic cells. Gene Therapy 1998; 5: 1575-1579.
8. Hildinger M, Fehse B, Hegewisch-Becker S et al. Dominant selection of haematopoietic progenitor cells with retroviral mdrl-coexpression vectors. Hum Gene Ther 1998; 9: 33-42.
9. Hildinger M, Schilz A, Eckert HG et al. Bicistronic retroviral vectors for combining myeloprotection with cell surface marking. Gene Therapy 1999; 6: 1222-1230.
10. Sorrentino BP, McDonagh KT, Woods D, Orlic D. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in haematopoietic cells of transplanted mice. Blood 1995; 86: 491-501.